Two Onc Docs

The podcast discusses the diagnosis, subtypes, and treatment of soft tissue sarcomas. It explores the molecular abnormalities associated with sarcomas and highlights common misdiagnosis. The importance of accurate pathology, staging, and prognostic factors for sarcomas is also covered. Treatment options for localized and metastatic sarcomas are discussed, including surgery, radiation, and targeted therapies. An overview of Kaposi's sarcoma and key takeaways on sarcoma treatment are provided.

This podcast discusses the management of ER positive HER2 negative breast cancer, including the NATALEE Trial on adding ribocyclib to endocrine therapy. They explore the use of CDK46 inhibitor, compare ribocyclib with aromatase inhibitor alone, and analyze its impact on localized breast cancer treatment. The episode also focuses on optimizing clinical trial design for reliable results and stresses the importance of further research on overall survival data.

Exploring frontline and second-line treatment options for metastatic RCC including combinations of tyrosine kinase inhibitors and immunotherapy agents based on risk criteria. Analysis of the CONTACT03 Trial outcomes revealing no significant difference between PDL-1 monoclonal antibody with cabozantinib compared to cabozantinib alone. Insights on response rates, challenges in subgroup analysis, and toxicity profile in metastatic RCC patients post-progressing on prior treatment. Discussion on negative study results, subgroup analysis complexities, and impact on treatment paradigms in oncology trials.

Join us for a recap on the treatment of rectal cancer, including a discussion on the PROSPECT Trial at ASCO 2023. Delve into the nuances of total neoadjuvant therapy, selective chemo radiation, non-inferiority trial design, and patient outcomes in rectal cancer treatment.

Exploring the nuances of rectal cancer diagnosis and treatment, highlighting total neoadjuvant therapy for improved outcomes. Discussions on advancements in treatment, including immunotherapy for locally advanced cases and comparisons between metastatic rectal and colon cancer treatments.

ASCO 2023 is just around the corner and we are teaming up with The Fellow On Call to bring you a joint mini-series called “Paging Heme/Onc: Updates from ASCO 2023” where we’ll bring you brief, high-yield discussions of some of the research we found most interesting from this year’s conference.

The podcast discusses indications for pre-transfusion protocols, infectious and non-infectious risks of transfusions, and acute & delayed risks. It also explores the management of transfusion reactions and serious complications like trolley and taco. Additionally, it covers anaphylactic reactions, post-transfusion perpura, transfusion graft-versus-host disease, infectious risks, and platelet refractoriness.

This week’s episode is part 1 of a 2 part series focusing on transfusion medicine. In part 1, we cover important details on blood group systems, blood components, indications for these components, and quickly cover apharesis. 

Explore the crucial steps in diagnosing thyroid cancer, staging, and treatments. Learn about the challenges of refractory thyroid cancer and targeted systemic therapies. Discover treatment options for anoplastic thyroid cancer and the significance of clinical trials. Delve into medullary thyroid cancer and targeted therapies for different cancer types.

This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.